A rapid screening system has been established to extract novel candidates that exhibit potent inhibition of the transport of fluorescent substrate by organic anion transporting polypeptide (OATP) 1B3. OATP1B3 is abundantly expressed in solid digestive organ cancers. Thus, the identification of new substrates leads to novel strategies for effective cancer chemotherapy with minimal adverse effects. We used an automated image substrates for OATP1B3, we performed transport assays in OATP1B3-expressing cells. We determined that SN-38 is a novel substrate for OATP1B3. In conclusion, our results demonstrate that the screening system established in this study is a useful method for the rapid extraction of candidate therapeutic agents from the large numbers of compounds.
Introduction
Organic anion transporting polypeptides (OATPs) are sodium-independent organic anion transporters expressed in a wide variety of tissues, including the liver, kidney, intestine, and brain. OATPs contribute to the transport of bile acids, thyroid hormones, steroid conjugates, anionic oligopeptides, eicosanoids, drugs, and other xenobiotic compounds across membranes [1] [2] [3] [4] . OATP1B3 (LST-2/OATP8), a member of the liver-specific subfamily of OATPs, localizes to the basolateral membrane of hepatocytes [5] [6] [7] [8] . OATP1B3 is also expressed by solid digestive organ neoplasms, including gastric, pancreatic, and colon cancers [7] . OATP1B3 is weakly expressed by the normal liver, but strongly upregulated by cancer cells. Thus, a greater understanding of the interaction between OATP1B3 and antineoplastic drugs would be useful to develop novel strategies for effective cancer chemotherapeutics with minimal adverse effects.
Fluorescent bile acids are efficiently transported by both OATP1B1 and OATP1B3 [9] .
We have recently succeeded in the visualization of the transport process using confocal imaging. We applied this imaging technique to the screening of transporter substrates. In this study, we examined the effects of antineoplastic drugs on the transport of fluorescent substrates via OATP1B3 using an automated image acquisition and analysis system (IN Cell Analyzer 1000). We have discovered a new substrate for OATP1B3, suggesting that this system can be instrumental in the rapid screening of novel candidate substrates.
Materials and Methods

Materials
Chenodeoxycholyl-(Nε-NBD)-lysine (CDCA-NBD) was synthesized as previously described [9] . Anti-OATP8 antibody was purchased from Affinity BioReagents, Inc. (Golden, CO). All other chemicals were commercially available and of the highest purity possible.
Cell culture and transfection studies
HEK293 cells, which are derived from human embryonic kidneys, were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in an atmosphere of 5% CO 2 , 95% air at 37°C. Cells were transfected with a pcDNA3.1(+) plasmid vector (Invitrogen) encoding OATP1B3 using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions. After three weeks of selection in G418 (0.5 mg/mL), we screened single colonies for OATP1B3 expression by immunoblot analysis and transport studies. Cells transfected with empty vector (HEK/pcDNA3.1(+)) were used as controls.
Immunoblot analysis.
Membrane fractions (15 g/lane) were separated by SDS-polyacylamide gel electrophoresis (8%). OATP1B3 was detected with a monoclonal anti-OATP8 antibody diluted 1:100, and detection was performed using Peroxidase-conjugated AffiniPure Goat Anti-Mouse IgG+IgM (H+L) (Jackson ImmunoResearch, West Grove, PA) diluted 1:10000.
Transport study.
We measured the cellular uptake of CDCA-NBD in monolayer cultures grown on 24-well plates. After washing once, cells were preincubated in Krebs-Henseleit buffer (118 mM NaCl, 23.8 mM NaHCO 3 , 4.83 mM KCl, 0.96 mM KH 2 PO 4 , 1.20 mM MgSO 4 , 12.5 mM HEPES, 5.0 mM glucose, and 1.53 mM CaCl 2 , pH 7.4). Uptake was initiated by adding CDCA-NBD to the medium. At the indicated times, uptake was terminated by replacement of the uptake buffer with ice-cold Krebs-Henseleit buffer containing 1% BSA. After washing two times in ice-cold BSA-free Krebs-Henseleit buffer, cells were lysed in lysis buffer (20 mM Tris with 0.4% Triton X-100, adjusted to pH 9.0). The fluorescence contained in each aliquot was measured using a microplate spectrofluorometer (SPECTRAmax GEMINI XS; Molecular Devices, Sunnyvale, CA) at an excitation wavelength of 485 nm and an emission wavelength of 538 nm.
Similarly, uptake of actinomycin D, mitoxantrone, and SN-38 were determined. Uptake of actinomycin D was measured by the fluorescence at an excitation wavelength of 360 nm and an emission wavelength of 480 nm. Mitoxantrone was determined at an excitation wavelength of 623 nm and an emission wavelength of 690 nm, and SN-38 was determined at an excitation wavelength of 380 nm and an emission wavelength of 540 nm
We measured the uptake of docetaxel and paclitaxel by monolayer cultures grown in six-well plates using high-performance liquid chromatography (HPLC). After terminating antineoplastic drug uptake, cells were scraped and homogenized in 1 mL of water. Known quantities of paclitaxel or docetaxel were added to each cell lysate sample as an internal standard. Antineoplastic drugs were extracted using 3-mL Bond Elut C18 cartridges (Varian, Harbor City, CA). The HPLC system consisted of a Nanospace SI-1 (Shiseido, Tokyo, Japan) equipped with an ultraviolet ray detector set at 230 nm. Chromatography utilized isocratic elution from a C18 Capcell Pak UG120 column (Shiseido; 1.5 × 150 mm, 5 μm) in acetonitrile-water (50:50, vol/vol, pH 4.0 with acetic acid) at a flow rate of 100 μL/min.
The protein content of the solubilized cells was determined using a Protein Assay kit (Bio-Rad Laboratories Inc., Hercules, CA). 
Screening of antineoplastic drugs
Statistical analysis.
Data are expressed as means ± S.E. When appropriate, the differences between groups were tested for significance using the unpaired Student's t test. Statistical significance was indicated by P values less than 0.05.
Results
Transport of CDCA-NBD by OATP1B3-transfected cells
First, we established stable clones overproducing OATP1B3. Clones that survived selection in 0.5 mg/mL G418 were expanded. Analysis for OATP1B3 overproduction by immunoblotting and CDCA-NBD uptake ( Fig. 1A and 1B ) isolated two clones, OATP1B3-9
and OATP1B3-10. OATP1B3-9 exhibited higher expression levels and transport activity of OATP1B3 than OATP1B3-10 (Fig. 1B) . Kinetic parameters in OATP1B3-9 were determined after exposure to varying concentrations of CDCA-NBD ( OATP1B3-mediated CDCA-NBD transport was also reduced by several previously reported substrates (inhibitors) (Fig. 1D) .
Screening of antineoplatstic drugs in OATP1B3-transfected cells
In this study, we examined the effects of antineoplastic drugs on OATP1B3-mediated transport of fluorescent substrates using an IN Cell Analyzer 1000 system. CDCA-NBD, which is efficiently transported by OATP1B3, was used as a fluorescent probe. Eighteen antineoplastic drugs with a variety of mechanisms of action were selected; BSP was used as a positive control. CDCA-NBD fluorescence intensity was measured using the IN Cell
Analyzer 1000 (Fig. 2) . The result of screening, three and nine antineoplastic drugs significantly inhibited CDCA-NBD transport at inhibitory concentrations of 5 and 20 µM, respectively (Table 1) . At higher inhibitory concentrations (20 µM), docetaxel, actinomycin D, mitoxantrone, paclitaxel, and SN-38 inhibited transport to a greater extent than methotrexate, a reported OATP1B3 substrate, and decreased the observed fluorescent intensities to 27, 61, 54, 50, and 49%, respectively.
Transport of antineoplastic drugs by OATP1B3-expressing cells
We examined the uptake study to clarify whether these five neoplastic agents were OATP1B3 substrates. SN-38 alone demonstrated significant transport by OATP1B3-expressing HEK293 cells (Fig. 3) . The other drugs were not significantly transported.
Discussion
In this study, we developed a screening system to extract antineoplastic candidates that are OATP1B3 substrates using an automated image acquisition and analysis system (IN Cell Analyzer 1000). As OATP1B3 is abundantly expressed in liver and other solid digestive organ cancers [7] , effective cancer chemotherapy could exploit the OATP1B3 protein to allow the increased accumulation of antineoplastic drugs in cancer cells.
CDCA-NBD is a fluorescent probe that is efficiently transported by OATP1B3 (Fig. 1) [9]. We are able to visualize the uptake of CDCA-NBD in living cells (Fig. 2) . Our initial screening revealed several potent inhibitors of CDCA-NBD uptake (docetaxel, actinomycin D, mitoxantrone, paclitaxel, and SN-38) ( Table 1 ). This result indicated that our novel screening system is highly informative. Interestingly, vinblastine and vincristine increased the uptake of CDCA-NBD. This result looks similar to the previous result of increased methotrexate uptake induced by vinblastine and vincristine [11] . It is possible that some of substrates for OATP1B3 are cis-stimulated by vinblastine and vincristine.
It is important to identify if each extracted antineoplastic candidate is a substrate for OATP1B3. We therefore examined uptake studies, in which candidate transport into the cells is directly measured (Fig. 3) . SN-38 was significantly transported into OATP1B3-9 cells.
OATP1B3-9 cells were more sensitive to SN-38 than mock cells by cytotoxicity assay (IC 50 value; 2.35 ± 0.45 for OATP1B3-9 and 3.92 ± 0.38 nM for mock cells, n= 4, P < 0.05). This is the first report that SN-38 is a substrate for OATP1B3. Previous reports have demonstrated that SN-38 is a substrate for OATP1B1, but not OATP1B3, which is inconsistent with our results [12] . In some case, different expression system for transporter protein makes different results. For example, taurocholic acid is reported to be a substrate for OATP1B3
using Xenopus leavis oocyte system but not a substrate using HEK293 system [7, 13] . The reason for these discrepancies is unclear. We could not, however, observe substantial transport of paclitaxel, docetaxel, mitoxantrone, or actinomycin D by OATP1B3-9 cells.
Paclitaxel and docetaxel are reported to be substrates for OATP1B3 in the Xenopus leavis oocytes expression system [8] . The discrepancy may result from differences in the transporter expression system.
In conclusion, we established a rapid screening using a fluorescent probe system to evaluate large numbers of antineoplastic candidates. From our screening results, this system is capable of identifying novel substrates for OATP1B3. Our results suggest that this screening system is useful for the rapid and exact extraction of the candidates from enormous numbers of compounds. experiments. *P < 0.05, significantly different from the uptake by mock cells. Fluorescence intensities were determined with the "Object Intensity Module" of the IN Cell Analyzer 1000. Each value represents the mean ± S.E. except for "events" (mean ± S.D.). "events" means cell numbers used for each experiment. *P< 0.05, significantly different from control. Uptake (pmol/mg protein) * * *
